- Home
- TARS
as of 03-20-2026 3:41pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.8B | IPO Year: | 2020 |
| Target Price: | $89.00 | AVG Volume (30 days): | 526.9K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | quarterly |
| EPS: | -1.59 | EPS Growth: | 48.21 |
| 52 Week Low/High: | $38.51 - $85.25 | Next Earning Date: | 04-30-2026 |
| Revenue: | $451,360,000 | Revenue Growth: | 146.71% |
| Revenue Growth (this year): | 55.67% | Revenue Growth (next year): | 30.64% |
| P/E Ratio: | -42.03 | Index: | N/A |
| Free Cash Flow: | -22310000.0 | FCF Growth: | N/A |
AI-Powered TARS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)
General Counsel
Avg Cost/Share
$67.00
Shares
4,231
Total Value
$283,477.00
Owned After
63,959
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$67.00
Shares
4,174
Total Value
$279,658.00
Owned After
35,028
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$67.00
Shares
4,589
Total Value
$307,463.00
Owned After
85,780
SEC Form 4
See Remarks
Avg Cost/Share
$67.00
Shares
2,186
Total Value
$146,462.00
Owned After
43,316
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$67.00
Shares
4,440
Total Value
$297,480.00
Owned After
61,480
SEC Form 4
President/CEO and Board Chair
Avg Cost/Share
$67.00
Shares
11,964
Total Value
$801,588.00
Owned After
33,421
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$67.00
Shares
390
Total Value
$26,130.00
Owned After
23,308
SEC Form 4
General Counsel
Avg Cost/Share
$68.71
Shares
4,125
Total Value
$283,428.75
Owned After
63,959
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$68.71
Shares
4,071
Total Value
$279,718.41
Owned After
35,028
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$68.71
Shares
3,610
Total Value
$248,043.10
Owned After
85,780
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Wahl Bryan | TARS | General Counsel | Mar 19, 2026 | Sell | $67.00 | 4,231 | $283,477.00 | 63,959 | |
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Mar 19, 2026 | Sell | $67.00 | 4,174 | $279,658.00 | 35,028 | |
| Neervannan Seshadri | TARS | Chief Operating Officer | Mar 19, 2026 | Sell | $67.00 | 4,589 | $307,463.00 | 85,780 | |
| Farrow Jeffrey S | TARS | See Remarks | Mar 19, 2026 | Sell | $67.00 | 2,186 | $146,462.00 | 43,316 | |
| Mottiwala Aziz | TARS | Chief Commercial Officer | Mar 19, 2026 | Sell | $67.00 | 4,440 | $297,480.00 | 61,480 | |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Mar 19, 2026 | Sell | $67.00 | 11,964 | $801,588.00 | 33,421 | |
| Lin Elizabeth Yeu | TARS | Chief Medical Officer | Mar 19, 2026 | Sell | $67.00 | 390 | $26,130.00 | 23,308 | |
| Wahl Bryan | TARS | General Counsel | Mar 18, 2026 | Sell | $68.71 | 4,125 | $283,428.75 | 63,959 | |
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Mar 18, 2026 | Sell | $68.71 | 4,071 | $279,718.41 | 35,028 | |
| Neervannan Seshadri | TARS | Chief Operating Officer | Mar 18, 2026 | Sell | $68.71 | 3,610 | $248,043.10 | 85,780 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 23, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 23, 2026 · 100% conf.
1D
-3.11%
$67.43
Act: +7.79%
5D
-6.93%
$64.77
Act: +11.27%
20D
-12.91%
$60.61
tars-202602230001819790FALSE00018197902026-02-232026-02-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 23, 2026
TARSUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-39614 81-4717861 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618 (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (949) 418-1801 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareTARSThe Nasdaq Global Market LLC (Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 23, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information, including Exhibit 99.1, is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated February 23, 2026
104Cover Page Interactive Data File (embedded within XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 23, 2026By: /s/ Jeffrey S. Farrow
Jeffrey S. Farrow
Chief Financial Officer and Chief Strategy Officer
(Principal Financial Officer and Principal Accounting Officer)
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
Q3 2025 Earnings
8-KNov 4, 2025
tars-202511040001819790FALSE00018197902025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) November 4, 2025
TARSUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-39614 81-4717861 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618 (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (949) 418-1801 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareTARSThe Nasdaq Stock Market LLC Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information, including Exhibit 99.1, is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated November 4, 2025.
104Cover Page Interactive Data File (embedded within XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TARSUS PHARMACEUTICALS, INC.
Date: November 4, 2025
/s/ Jeffrey Farrow Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer (Principal Financial Officer and Principal Accounting Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
Q2 2025 Earnings
8-KAug 6, 2025
tars-202508060001819790FALSE00018197902025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported) August 6, 2025
TARSUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-39614 81-4717861 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618 (Address of principal executive offices, including Zip Code) Registrant's telephone number, including area code: (949) 418-1801 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareTARSThe Nasdaq Stock Market LLC Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information, including Exhibit 99.1, is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated August 6, 2025.
104Cover Page Interactive Data File (embedded within XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TARSUS PHARMACEUTICALS, INC.
Date: August 6, 2025
/s/ Jeffrey Farrow Jeffrey Farrow Chief Financial Officer and Chief Strategy Officer (Principal Financial Officer and Principal Accounting Officer)
Compare TARS vs Leading Stocks
See how TARS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.